AzTrials
AzTrials

TelemedicineInfluenz-erNCT05087082

Early Transfer of Hospitalized Patients Incl. COVID-19 to a Virtual Hospital at Home Model - a Clinical Feasibility Study

A study testing Virtual Hospital at Home - Home admission of epidemic patients in people with Telemedicine and Epidemic Disease, run by Nordsjaellands Hospital at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study will be part of a larger, 'virtual hospital-at-home' (vHaH) project called Influenz-er. vHaH is a care model designed to deliver medical care in the home, as a substitute for a continued inpatient hospital admission. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Telemedicine, Epidemic Disease
What is being tested?
Virtual Hospital at Home - Home admission of epidemic patients
Could I receive a placebo?
No, everyone receives an active treatment
How many people
19 participants
Where
1 siteDenmark
Study dates
20 Apr 2022to 20 Sep 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥ 18 years of age
  • Signed informed written and oral consent
  • Lower tract respiratory infections, including contagious infection (e.g. SARS CoV 2 and Influenza).
  • Considered not ready for discharge for at least 24 hours, assessed by attending MD in the COVID-19 ward.
  • Patients are self-reliant or receives sufficient formal care to be care-independent of primary informal caregiver
  • - Medically eligible for vHaH, including but not solely dependent of following conditions, assessed by the attending VEC MD:
Show all 12Show fewer
  • Actual condition assessed to be clinically stable.
  • Green or yellow-tag triage based on vital parameters, including total adjusted EWS-score ≤6 and no adjusted single parameter score of 3 or above (See appendix 1)
  • Requires less than 5L/min of oxygen supplement
  • Stable or decreasing need for oxygen supplement
  • Stable or decreasing paraclinical infection parameters such as C-reactive protein (CRP) etc.
  • Home-based admission will be located within catchment area of the hospital (according to the official address of the individual).

Who cannot join

  • Patients who cannot participate in interaction via App
  • Lack of sufficient Danish language skills to understand and interact with requirements and staff at a patient safe level
  • Patient residency cannot offer isolated room (COVID-19 patients only)
  • Pregnancy
  • Inclusion criteria specific for primary informal caregivers (if any)
  • Signed informed written and oral consent
  • Study patient is included in the study
  • Age ≥ 18 years

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Nordsjaellands Hospital

    Hillerød, 3400

Other trials in Denmark

About this study

Official title: Early Transfer of Hospitalized Patients Including COVID-19 Patients to a Virtual Hospital at Home(vHaH)Model -a Clinical Feasibility Study.

This study will be part of a larger, 'virtual hospital-at-home' (vHaH) project called Influenz-er. vHaH is a care model designed to deliver medical care in the home, as a substitute for a continued inpatient hospital admission. This study will be a clinical feasibility study, which will be used to guide the framing and design of the final telemedicine supported vHaH model for hospitalized patients.

Read the detailed description

This study will be part of a larger, 'virtual hospital-at-home' (vHaH) project called Influenz-er. vHaH is a care model designed to deliver medical care in the home, as a substitute for a continued inpatient hospital admission. An underlying rationale for the development of vHaH is that, by avoiding the hospital environment, fragile and older persons may experience high-quality care that is associated with fewer complications, and higher treatment satisfaction for patients and their families. Various versions of home-hospital models have been implemented during the COVID-19 pandemic crisis, but in many situations out of need and so far, only very limited documented experience from sound research approaches is available in the medical literature. This study will be a clinical feasibility study, which will be used to guide the framing and design of the final telemedicine supported vHaH model for hospitalized patients including epidemic patients. We apply our experience from 5 months of clinical small scale testing (Sept 2021 - Jan 2022) of the light version of the final vHaH model on hospitalized patients (the technology and workflows of the vHaH model were tested by in-patients under their hospital stay) to implement this novel model in the safest possible way. The vHaH model will be offered exclusively to moderately ill (not severely ill) patients with respiratory infections including COVID-19.

The overall aim of Influenz-er, is to develop and implement a novel telemedicine monitoring and communication model, that will enable safe admission of epidemic patients in their homes. We will implement this novel model in the safest possible way, and initially offer the vHaH model to patients conventionally admitted with COVID-19 illness or other lower respiratory tract infections causing pneumonia. Conversion to vHaH admission will be effectuated after an assessment by a medical infectious disease specialist if the patient is assessed to be ready to continue the hospital admission safely from home, under continued monitoring and treatment responsibility by the hospital.

Based on a Cochrane review this innovative alternative to conventional hospitalization, is expected to benefit patients who will remain in the comfort of their own homes. This model could potentially increase patient and next of kin quality of life and treatment satisfaction, decrease risks of nosocomial complications and increase availability of emotional support from next of kin.

A hospital based Virtual Epidemic Center (VEC) is the center of the project, from where medical staff will monitor and communicate with patients admitted at home. Vital parameters and patient reported outcomes will be collected using a smart phone/tablet-based app. All data will be collected and processed in an algorithm to predict the impact of changes on disease severity. Algorithm and direct patient data will be displayed in real-time at the hospital in the VEC, allowing medical staff to continuously monitor their patients. In addition, daily virtual ward rounds conducted by staff in the VEC and when relevant by medical doctors (MD) from specialties of relevance to the patients' illness(es) will ensure close communication and relevant clinical assessments. A mobile medical team consisting of nurses and medical doctors (MD), will perform in-person patient evaluations, administer medication and perform other required daytime routine medical tasks.

The Influenz-er project governance structure consists of a Steering Committee with representation by the project partners Nordsjællands Hospital, University of Southern Denmark and Innovation Fund Denmark, an international Advisory Board and a national Consulting Group. Head of Clinical Research at Nordsjællands Hospital, Professor Thea Kølsen Fischer is principle investigator and project manager. The project team includes clinical experts with expertise within management of COVID-19 as well as health economic senior experts, PhD students, administrative research and innovation coordinators and health tech developers.

The objective of this feasibility study is to investigate and analyze relevant factors for admitting adult patients with LTRI including COVID-19 in a vHaH model to ascertain the likelihood of completing the vHaH model successfully.

Enrolment: Potential study patients will be identified by the general healthcare staff of the hospital COVID-19 ward, after a minimum of 24 hours of observation and conventional care, in order to ensure that the patients are in a stable phase of the disease. The healthcare staff of the hospital COVID-19 ward will be trained in, and instructed to, recognize potential eligible patients and subsequently inform the attending study personnel in the VEC. Study personnel will then assess the patients in the ward. The patients will receive oral and written information regarding the study and will be asked if they can identify a next of kin as a primary informal caregiver. Primary informal caregivers can be anyone and does not necessarily have to live with the patients or be the person who spends most time with the patients. The patients are not required to identify a primary informal caregiver in order to participate in the study. Patients with children in their household are not necessarily excluded, as the guidelines mention how to accommodate kids in the household. Current guidelines regarding self-isolation of SARS-CoV-2 positive individuals given by the Danish government will be applicable for patients admitted at home and their primary informal caregivers.

If the patients do identify a primary informal caregiver this person will be contacted and the oral and written information regarding the study, will be repeated for the identified primary informal caregivers. Study consent is obtained electronically via REDCap from patients and primary informal caregivers (if any) who are still interested in participating after having received information regarding the study. This is followed by the generation of an inclusion-ID for each via REDCap. To ensure that identified primary informal caregivers are taken into consideration, it is a requirement that both patients and primary informal caregivers agree to participate in the study. The study patients must accept that primary informal caregivers have the rights to terminate the HaH-admission and demand the conversion of the HaH-admission to a conventional hospital admission at any time. If potential study patients do not accept this term it will be considered as an exclusion criterion and the patients will not be considered eligible for the study.

Subsequently, the patients will be formally assessed for inclusion, in accordance with inclusion- and exclusion criteria. Included patients and primary informal caregivers (if any) will get a formal study-ID each. Study patients will receive and install the study app on a compatible device and the study personnel will ensure that study patients are educated in the basic functionality of the app.

Patients who do not meet the inclusion criteria will be either permanently or temporarily excluded and will retain their inclusion-ID. Age, gender and the reason of exclusion will be noted.

The first set of biometric data will be obtained within the hospital, assisted by the staff in order to secure the proper usage of the equipment. Furthermore, study patients will be equipped with a direct phone number for the VEC, which they can use to contact the personnel in the VEC independently from the app. All study patients are instructed to contact 112 in the case of a medical emergency requiring immediate medical assistance.

The study patients will be instructed to measure and upload biometrical data (body temperature, blood pressure, heart rate, respiratory frequency, oxygen saturation, blood glucose) at a frequency specified by the attending Medical Doctor (MD) in accordance with medical assessment, according to standard hospital early warning score (EWS)-screening. Furthermore, patients will be instructed to complete and upload the self-assessment questionnaire along with all biometric uploads using the app. Study patients with controlled comorbidities will be monitored and treated as per usual according to local applicable guidelines, and medical specialists will be available for collegial sparring as is the case during a conventional hospitalization.

The app will notify the study patients when it is time to upload a new set of biometrical and self-assessed data and notify upcoming planned virtual ward rounds. Adjustments to surveillance level will be communicated directly to study patients by attending personnel in the VEC.

After all relevant information has been confidently delivered and the patient has demonstrated capability to use the app correctly the study patients will be admitted at home by the VEC MD on duty. All study patients will be offered a free transfer home. If the study patients are still dependent on supplemental oxygen this will be installed in their home prior to the home admission, and the patients and their relatives will receive thorough instructions in how to use the oxygen equipment as well as how to behave with oxygen equipment at home.

Being tested
Virtual Hospital at Home - Home admission of epidemic patients

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Virtual Hospital at Home - Home admission of epidemic patientsOther

    Admitting COVID-19 patients at home

Study groups in NCT05087082
Study groupRoleWhat they receive
App and Case Management system with algorithmsOtherFeasibility study of hospital at home model including telemedicine and specifically developed app and case management system
Receives: Other: Virtual Hospital at Home - Home admission of epidemic patients

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of all planned daily video supported ward rounds provided

    successful protocol adherence is defined by 80%

    Measured: through study completion, approximately 18 months

  2. Percentage of all planned self-measurements transmitted by patient

    successful protocol adherence is defined by 80%

    Measured: through study completion, approximately 18 months

  3. Percentage of all acute contact requests from patients handled within pre-defined time

    successful protocol adherence is defined by 80%

    Measured: through study completion, approximately 18 months

  4. Percentage of all non-acute contact requests from patients handled within pre-defined time

    successful protocol adherence is defined by 80%

    Measured: through study completion, approximately 18 months

  5. Percentage of all red alarms triggered by EWS-change handled within pre-defined time

    successful protocol adherence is defined by 80%

    Measured: through study completion, approximately 18 months

  6. Percentage of all yellow alarms triggered by EWS-change handled within pre-defined time

    successful protocol adherence is defined by 80%

    Measured: through study completion, approximately 18 months

  7. Number of recruited participants

    recruitment success is defined as 80%

    Measured: through study completion, approximately 18 months

  8. Number of drop-out participants

    success is defined by brop out less than 10%

    Measured: through study completion, approximately 18 months

  9. Number and type of outcome assessment completed by participants.

    Measured: through study completion, approximately 18 months

Secondary outcomes (18)
  1. Patient related endpoints: Compound of clinical events

    Compound of clinical events:

    • Health care associated infections during home-based admission
    • Delirium during home-based admission
    • Thromboembolic events during home-based admission
    • Admittance to intensive care unit (ICU) during home-based admission
    • Respirator treatment following home-based admission
    • Intravenous antibiotic treatment during home-based admission
    • Intravenous antiviral treatment during home-based admission
    • Thirty-day readmittance rate post discharge
    • Mortality (associated, 7 days and 30 days)

    Measured: 30 days efter the discharge.

  2. Patient related endpoints: Loss of function

    SF-36

    Measured: Three months after discharge

  3. Patient related endpoints: Productivity losses

    Number of days patient is absent from work during the period of sickness in relation to the admission, number of days patient is not able to perform daily tasks such as cooking, grocery shopping and house cleaning during the period of sickness in relation to the admission and number of days in isolation during the period of sickness in relation to the admission

    Measured: Three months after discharge of patient

  4. Patient related endpoints: Self-perceived quality of care

    Questionnaire 5

    Measured: Three months after discharge of patient

  5. Next of kin related endpoints: Quality of Life

    SF-36 (Questionnaire 3)

    Measured: Three months after discharge of patient

  6. Next of kin related endpoints: Quality of Life

    EQ-5D-5L

    Measured: Three months after discharge of patient

  7. Next of kin related endpoints: Caregiver strain

    Zarit Burden Interview (Questionnaire 6)

    Measured: Two weeks after discharge of the patient

  8. Next of kin related endpoints: Productivity losses

    Number of days next-of-kin is absent from work during the period of sickness of the patient in relation to the admission, number of days next-of-kin is not able to perform daily tasks such as cooking, grocery shopping and house cleaning during the period of sickness of the patient in relation to the admission and number of days in isolation during the period of sickness of the patient in relation to the admission

    Measured: Three months after discharge of patient

  9. Organizational related endpoints: Costs of hospital resource use

    Economic outcome

    Measured: Three months after discharge of patient

  10. Organizational related endpoints: Number of contacts to general practitioner

    Economic outcome

    Measured: Three months after discharge of patient

  11. Organizational related endpoints: Costs of general practitioner resource use

    Economic outcome

    Measured: Three months after discharge of patient

  12. Organizational related endpoints: Total costs of health care utilization per patient

    Economic outcome

    Measured: Three months after discharge of patient

  13. Organizational related endpoints: Intervention costs

    Economic outcome

    Measured: Three months after discharge of patient

  14. Organizational related endpoints: Number of in-hospital days

    Economic outcome

    Measured: Three months after discharge of patient

  15. Organizational related endpoints: Number of outpatient visits

    Economic outcome

    Measured: Three months after discharge of patient

  16. Organizational related endpoints: Productivity losses

    Economic outcome: A calculation of the costs in relation to the home admission of the patients during the feasibility study.

    Measured: Three months after discharge of patient

  17. Health-related Quality of Life

    SF36

    Measured: Three months after discharge of patient

  18. Health-related Quality of Life

    EQ-5D-5L

    Measured: Three months after discharge of patient

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Oct 2021
  2. Study start20 Apr 2022
  3. Primary completion20 Sep 2023
  4. Study completion20 Sep 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Model description
The study is a clinical feasibility study. We anticipate to enroll 20 participants. Participants are admitted patients with a lower respiratory infection are 18 years of age or older and have been admitted at the hospital for at least 24 hour. additionally they must be and are considered suitable for home admission according o the inclusion- and exclusion criteria. The participants will be a part of the study until discharge or withdrawal of consent. If a next-of-kin is identified as primary informal caregiver this person is offered to take participate in the study as well. Follow-up questionnaires will be sent to all participants, and follow-up interviews will be performed after discharge.
Masking
None (open label)
Enrolment
19 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05087082
Sponsor's protocol ID
H-21014302
Acronym
Influenz-er
Status last verified
Jun 2023
First submitted
18 Aug 2021
Last updated
28 Sep 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Uldbjerg K, Schonning SH, Dreisig TS, Nielsen SG, Larsen MN, Nielsen TL, von Sydow CD, Fischer TK, Olesen ML. Caring beyond hospital walls: Informal caregivers' experiences in a virtual and in-person hybrid hospital-at-home. BMC Health Serv Res. 2026 Apr 25;26(1):824. doi: 10.1186/s12913-026-14600-4.

    PubMed 42035034
  • Dreisig TS, Larsen M, von Sydow C, Nielsen T, Fischer TK, Overbeck G, Villadsen S. By the book or beyond? Lessons on implementation fidelity in remote patient monitoring within a hybrid hospital-at-home feasibility study. BMJ Health Care Inform. 2026 Feb 18;33(1):e101832. doi: 10.1136/bmjhci-2025-101832.

    PubMed 41708158
  • Sandreva T, Larsen MN, Rasmussen MK, Nielsen TL, von Sydow C, Schmidt TA, Fischer TK. Transforming health care: Investigating Influenzer, a novel telemedicine-supported early discharge program for patients with lower respiratory tract infection: A non-randomized feasibility study. J Telemed Telecare. 2025 Sep;31(8):1138-1151. doi: 10.1177/1357633X241254572. Epub 2024 May 23.

    PubMed 38780386

Questions about this trial

What is this clinical trial studying?

A study testing Virtual Hospital at Home - Home admission of epidemic patients in people with Telemedicine and Epidemic Disease, run by Nordsjaellands Hospital at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of all planned daily video supported ward rounds provided (time frame: through study completion, approximately 18 months). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05087082, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in